BiotechTube

Bumetanide + Furosemide

Phase 3Recruiting
2 views this week 0 watching⚡ Active🏛️Featured in Big Pharma Pipeline
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Cirrhosis

Conditions

Cirrhosis

Trial Timeline

Mar 1, 2026 → Mar 31, 2029

NCT ID
NCT06941415

About Bumetanide + Furosemide

Bumetanide + Furosemide is a phase 3 stage product being developed by Johnson & Johnson for Cirrhosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06941415. Target conditions include Cirrhosis.

What happened to similar drugs?

6 of 10 similar drugs in Cirrhosis were approved

Approved (6) Terminated (0) Active (4)
🔄peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
✅Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
✅Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)NovartisApproved
✅Telbivudine + Enecavir + AdefovirNovartisApproved
🔄Seladelpar 5 mg Capsule + Seladelpar 10 mg CapsuleGilead SciencesPhase 3
✅abataceptBristol Myers SquibbApproved
✅losartan (drug)LundbeckApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06941415Phase 3Recruiting

Competing Products

20 competing products in Cirrhosis

See all competitors
ProductCompanyStageHype Score
SYNB1020SynlogicPhase 1/2
14
peginterferon alfa-2a 180μg + peginterferon alfa-2a 90μg + ribavirinChugai PharmaceuticalPhase 3
40
Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle)ShionogiPhase 2
35
Mesenchymal Stem CellRohto PharmaceuticalPre-clinical
26
Mesenchymal stem cellRohto PharmaceuticalPhase 1/2
32
ZibotentanAstraZenecaPhase 1
29
Part A: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part A: zibotentan (dose B) + dapagliflozin + Part B: Placebo (matching zibotentan capsule & matching dapagliflozin tablet) + Part B: placebo (matching zibotentan capsule) + dapagliflozin + Part B: zibotentan (dose A) + dapagliflozin + Part B: zibotentan (dose B) + dapagliflozin + Part B: zibotentan (dose C) + dapagliflozinAstraZenecaPhase 2
27
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet) + Zibotentan + placebo (placebo matching dapagliflozin tablet) + Zibotentan + dapagliflozinAstraZenecaPhase 2
35
ARQ 197MerckPhase 1
29
Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBVMerckApproved
39
Steroids + Basiliximab + Tacrolimus + Enteric-coated Mycophenolic acid (EC-MPA)NovartisApproved
43
Telbivudine + Enecavir + AdefovirNovartisApproved
39
Serelaxin + PlaceboNovartisPhase 2
35
Terlipressin acetate + Serelaxin (RLX030)NovartisPhase 2
35
PasireotideNovartisPhase 1
29
HPN-100 + PlaceboAmgenPhase 2
35
Placebo Comparator + Experimental: Seladelpar 50 mg + Experimental: Seladelpar / MBX-8025 200 mgGilead SciencesPhase 2
27
TDF/FTC/LPV/r + PlaceboGilead SciencesPre-clinical
18
MBX-8025 2 mg Capsule + MBX-8025 5 mg Capsule + MBX-8025 10 mg CapsuleGilead SciencesPhase 2
35
Seladelpar 5 mg Capsule + Seladelpar 10 mg CapsuleGilead SciencesPhase 3
44